For Ipsen, aligning with a partner on data-driven success criteria is not a post-deal task but a prerequisite for signing. If the parties cannot agree upfront on what defines success for a program, they will not proceed with the partnership, ensuring discipline and preventing future misalignments.
Ipsen views its R&D strategy as accelerating innovation sourced from academia and biotech. It leverages its strengths in clinical, regulatory, and commercialization to complement the focused discovery work done by smaller partners, acting as a catalyst within the broader life sciences ecosystem rather than just a buyer.
To foster accountability for external assets, Ipsen integrates its innovation and scouting teams directly into the R&D organization, rather than siloing them with business development. This ensures partnered programs have a natural home and are not seen as competition to internal efforts, preventing cultural friction.